FDA approved Regeneron's Pasatru (garetosmab) for FOP, a rare disease affecting ~900 patients. Annual list price ranges $693K–$2.1M based on weight.
Regeneron has secured approval for its treatment for a debilitating disease that replaces muscle and connective tissue with bone.
The FDA on Wednesday cleared the …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Regeneron Secures FDA Approval For Ultra-Rare Bone Disorder Drug - Regeneron Pharmaceuticals (NASDAQ:REGN
Regeneron's Pasatru scores FDA approval in ultrarare bone lesions disorder
Regeneron drug for disease that causes dangerous bone growth earns FDA approval
Regeneron to challenge Ipsen as FDA clears bone disease drug
FDA approves Pasatru to reduce lesions, flare-ups in fibrodysplasia ossificans progressiva
FDA Approves Activin Signaling Inhibitor for Bone Disorder
Pharmalittle: We're reading about a Regeneron rare disease drug, an Ultragenyx gene therapy, and more
FDA approves Ultragenyx gene therapy
Ultragenyx Nabs FDA Nod for First Gene Therapy - Ultragenyx Pharmaceutical (NASDAQ:RARE)
FDA approves first gene therapy to treat glycogen storage disease type Ia
Regeneron Pharmaceuticals secured FDA approval for Pasatru, a novel monthly infusion therapy proven to reduce lesions in FOP…
After more than 10 years in development, Regeneron secured a landmark approval for its monoclonal antibody garetosmab, now…
A Regeneron drug that treats an ultra-rare disease that causes bone to form where it's not meant to be has won approval.
Pasatru’s approval sets up a market battle in a rare indication where the only available treatment has generated disappointing…
The FDA approved a novel therapy for reducing the formation of heterotopic ossification lesions and flare-ups for adults with…
Ultra-rare fibrodysplasia ossificans progressiva now has its second approved drug
